|Mr. Frederic Chereau M.B.A.||Pres, CEO & Director||632.9k||N/A||1967|
|Dr. Mark A. Kay||Co-Founder & Independent Director||102.5k||N/A||1958|
|Dr. Leszek Lisowski Ph.D.||Co-Founder||N/A||N/A||N/A|
|Dr. Adi Barzel Ph.D.||Co-Founder||N/A||N/A||N/A|
|Mr. Matthias B. JaffÃ©||Chief Financial Officer||N/A||N/A||1968|
|Dr. Kyle Chiang Ph.D.||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Matthias Hebben||Global VP & Head of Technology Devel.||N/A||N/A||N/A|
|Mr. Brian Luque||Associate Director of Investor Relations||N/A||N/A||N/A|
|Dr. Daniel J. Gruskin M.D.||Sr. VP & Head of Clinical Devel.||N/A||N/A||N/A|
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was founded in 2014 and is headquartered in Lexington, Massachusetts.
LogicBio Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 6; Compensation: 8.